Own stem cells tested to fight liver scarring in 700 patients

NCT ID NCT05080465

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 3 study followed 700 people with liver cirrhosis caused by hepatitis B, C, or fatty liver disease. Researchers took a small amount of bone marrow from each patient, processed it to collect stem cells, and infused those cells back into the patient. The goal was to check safety and see if the treatment could improve liver stiffness and blood markers of liver function over the long term.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
autologous bone marrow mesenchymal stem cells
What this could lead to
If successful, this could offer a way to slow or improve liver cirrhosis using a patient's own stem cells, potentially reducing the need for a liver transplant.
What could go wrong
This is a follow-up study, not a new treatment test, and results may not confirm lasting benefit. Stem cell therapy carries risks like infection or immune reactions, and cirrhosis is a complex disease that may not respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Digestive System Diseases Fibrosis liver disorder Pathologic Processes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institute of Bio-Stem Cell Rehabilitation

    Kharkiv, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.